Remove Clinical Development Remove Drug Delivery Systems Remove Trials
article thumbnail

Decoy-20 by Indaptus Therapeutics for Hepatocellular Carcinoma: Likelihood of Approval

Pharmaceutical Technology

Decoy-20 is under clinical development by Indaptus Therapeutics and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase I drugs for Hepatocellular Carcinoma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.

article thumbnail

Hydrocortisone by Antares Pharma for Adrenal Insufficiency: Likelihood of Approval

Pharmaceutical Technology

Hydrocortisone is under clinical development by Antares Pharma and currently in Phase I for Adrenal Insufficiency. According to GlobalData, Phase I drugs for Adrenal Insufficiency have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Top Emerging Therapies To Watch Out for in the Retinal Vein Occlusion Market

Delveinsight

Therapies such as dexamethasone drug delivery system and vascular endothelial growth factor inhibitors have already pierced deeper into the market. Looking at its potential, the drug is also being watched out in diabetic macular edema in combination with intravitreal anti-VEGF drugs.

article thumbnail

Skin Cancer Awareness Month 2024 and Insights from Medicus Pharma

XTalks

XTALKS WEBINAR: Enhancing Efficiency in Early-Phase Oncology Trials: Strategies for Accelerating Data Flow Live and On-Demand: June 24, 2024, at 11am EDT (4pm BST/UK) Register for this webinar today to gain insights into how you can navigate and overcome data flow challenges in early-phase oncology clinical trials.

article thumbnail

PCI Pharma Services Invests Over $365 Million in EU, US Facilities to Drive Clinical and Commercial Supply of Advanced Drug Delivery and Drug Device Combination Products

XTalks

This initiative focuses on enhancing infrastructure to support the clinical and commercial-scale final assembly and packaging of drug-device combination products, emphasizing advanced drug delivery systems, particularly injectable formats. For more information, visit pci.com.